XOBBAIM — 1877752
Application number
1877752
Type(s)
Word
Category
Trademark
CIPO Status
ABANDONED SECTION 36
TM5 status
DEAD/APPLICATION/
Withdrawn/Abandoned
The owner of the trademark application withdrew (e.g. abandoned) the application and the application is no longer active.
Filed
2018-01-16
Applicant
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
UNITED STATES OF AMERICA
Agent
SMART & BIGGAR LP
SCOTIA PLAZA
40 KING STREET WEST
40th FLOOR
TORONTO
ONTARIO M5H3Y2
Documents
Index headings
- XOBBAIM
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, anxiety and cognitive disorders, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the prevention and treatment of cranial and facial nerve disorders, connective tissue injuries, diseases and disorders, bone and cartilage injuries, diseases and disorders; pharmaceutical preparations for the prevention and treatment of neuromuscular and neurological diseases and disorders, namely, central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, muscle diseases and disorders, namely inflammatory muscle diseases and disorders and muscular dystrophy, ocular motility and spinal cord infections, injuries and diseases, and seizure disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, inflammatory pelvic, vaginitis, dysmenorrhea, cervix erosion, cervicitis, trachelitis, uterine cervicitis, endomitriosis, sexually transmitted diseases, erectile and sexual dysfunction, infertility and incontinence; pharmaceutical preparations for the prevention and treatment of cardiovascular, gastrointestinal, hematologic, oncological, ophthalmological and respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immunediseases and disorders, namely collagen disease, rheumatoid arthritis, systemic lupus erythematosus, alopecia areata, and systemic sclerosis; pharmaceutical preparations for the prevention and treatment of allergies, hypertension, menopause, diabetic neuropathy, arthritis, and pain; antibiotics, anti-infectives, anti-inflammatories, anti-fungals, anti-virals, oral and injectable pharmaceutical contraceptives, human vaccines; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; pharmaceutical preparations for the prevention and treatment of renal disease and disorders; pharmaceutical preparations for the prevention and treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of muscular atrophy; pharmaceutical preparations for the prevention and treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, muscular dystrophy, sickle cell disease, non-alcoholic steatohepatitis and anemia; pharmaceutical preparations for the prevention and treatment of dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, acne, pyoderma, erosion, ulcer, trauma, burned skin, pain and inflammation
Claims
- Proposed Use in CANADA
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2018-01-16 | ||
| Created | 2018-01-17 | ||
| Formalized | 2018-01-18 | ||
| Search Recorded | 2019-03-08 | ||
| Examiner's First Report | 2019-03-08 | 2019-09-08 | |
| Default Notice Sent | 2019-10-01 | 2019-12-01 | |
| Abandoned - Section 36 | 2019-12-24 |